Breitmeyer James B

Chief Executive Officer, DirectorOncternal Therapeutics, Inc. (ONCT) · full profile →Form 4 · filed Oct 4, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
24
0 non-derivative · 24 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 2, 2023Disposed to issuer(D)22K0
Oct 2, 2023Disposed to issuer(D)7K0
Oct 2, 2023Disposed to issuer(D)2K0
Oct 2, 2023Disposed to issuer(D)165K0
Oct 2, 2023Disposed to issuer(D)13K0
Oct 2, 2023Disposed to issuer(D)65K0
Oct 2, 2023Grant(A)22K12K
Oct 2, 2023Grant(A)7K7K
Oct 2, 2023Grant(A)2K2K
Oct 2, 2023Grant(A)165K165K
Oct 2, 2023Grant(A)13K13K
Oct 2, 2023Grant(A)65K65K
Oct 2, 2023Disposed to issuer(D)100K0
Oct 2, 2023Disposed to issuer(D)67K0
Oct 2, 2023Disposed to issuer(D)750K0
Oct 2, 2023Disposed to issuer(D)637K0
Oct 2, 2023Disposed to issuer(D)124K0
Oct 2, 2023Disposed to issuer(D)650K0
Oct 2, 2023Grant(A)100K100K
Oct 2, 2023Grant(A)67K67K
Oct 2, 2023Grant(A)750K750K
Oct 2, 2023Grant(A)637K637K
Oct 2, 2023Grant(A)124K124K
Oct 2, 2023Grant(A)650K650K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-052019) within minutes of acceptance. Every field above traces to the original document. Verify it directly: